The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | The importance of MRD in multiple myeloma patients
Bruno Paiva, PhD from the University of Navarra, Pamplona, Spain outlines his presentation on the role of minimal residual disease (MRD) in multiple myeloma, specifically its role as a prognostic factor and in the future as a biomarker to aid in treatment decisions. Dr Paiva, outlines the importance of studying the biology of tumor resistant clones at the MRD level. The first reason discussed is to understand the mechanisms of ultra-chemoresistance in order to develop novel targets and therapy combinations. The second is to understand the biology and genetic features of the MRD cell. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
